12 May 2022
May 12, 2022, Moscow – R&D Center NovaMedica Innotech has celebrated its 5th anniversary. The Center was created during implementation of the R&D strategy of its parent company NovaMedica (RUSNANO’s portfolio asset), which is 10 years old this year. Innotech does projects under NovaMedica’s own R&D program and offers to its partners services in development of new drugs and in contract manufacturing of solid dosage forms.
Elena LITVINOVA, Director General of NovaMedica (Innotech’s parent company):
“We conceived the idea of our R&D center as a modern pharmaceutical hub specializing in development of innovative dosage forms that, for example, improve bioavailability or other properties of active ingredients. Such solutions may also combine several active ingredients in one form to help the products find new applications and fundamentally surpass the existing drugs in efficacy and safety. These products can be called improved generics or smart innovations. We are proud of the fact that Innotech’s portfolio has a sizeable number of successful projects like this, including our Mioreol, NovaMedica’s first own CNS drug for the treatment of dementia associated with Alzheimer’s disease”.
Timofey PETROV, Director General of the R&D Center NovaMedica Innotech
«At the time Innotech was opened the market of R&D services had only started forming in Russia. Most of our clients, whom we have been helping with development of new drugs for 5 years already, were forced to approach European and American technological companies for help. Now, they come to us, and then they return and recommend us to other market players”.
In 5 years, more than 50 Russian and foreign companies have become partners of Innotech. Experts of the analytical and technological laboratories of the R&D Center have worked on and successfully completed over 70 research projects in development of pharmaceutical products for the treatment of CNS and cardiovascular diseases, for antiviral and anti-HIV therapy, and other drugs.
Today, NovaMedica Innotech provides packaged services to 27 pharmaceutical companies – from drug development and registration to contract manufacturing. Innotech is currently working simultaneously on 55 projects. The capacity of the manufacturing site allows producing up to 150 million drug units per year, including tablets, pellets, soft and hard gelatin capsules.
Timofey PETROV, Director General of the R&D Center NovaMedica Innotech:
“Thanks to our professional team and accumulated experience, we manage to launch manufacturing of new products as quickly as practicable. We are ready to use all of our competences and capabilities to at least double the number of projects and manufacturing capacity. I hope that soon we will announce the launch of some extremely important services, which the Russian R&D market needs very much at the moment."
Due to its unique equipment, Innotech is currently able to perform tasks related to modification of drug products’ properties. Most of the technologies that it uses have no equivalents in the Russian pharmaceutical industry at the moment. Apart from research, the R&D Center’s manufacturing and laboratory capacities allow scaling up technological processes, transferring pharmaceutical technologies, producing samples for clinical trials, as well as carrying out pilot, small-batch and commercial manufacturing.
Olga SHPICHKO, Deputy Chair of the Board of Directors of NovaMedica, Managing Director for Investments at RUSNANO Management Company:
Advancement of the R&D industry in Russia is of the highest significance, as, on the one hand, it is an indicator of social and economic development of the state, and on the other hand, it is a link in the chain of import substitution in this extremely important high-tech sector of our country. We are glad to see that the R&D Center NovaMedica Innotech has gained its feet and we are proud of its growing popularity and successes”
Information on the companies:
R&D Center NovaMedica Innotech is a 100% subsidiary of NovaMedica, Skolkovo resident. NovaMedica Innotech has state-of-the-art technological capabilities and conducts research, development and manufacturing of drugs in full compliance with the GMP standards, including on a contract basis. Manufacturing capacity of the R&D center NovaMedica Innotech is up to 150 million drug units per year (tablets, soft and hard gelatin capsules with various fillers: micro-tablets, pellets, granules, powders).
NovaMedica is a Russian pharmaceutical company created in 2012 by RUSNANO and the US venture fund Domain Associates LLC. NovaMedica’s strategy is aimed at search and localization in Russia of innovative pharmaceutical products and creation of new drugs under its own R&D program. Some of these products already have marketing authorizations. Exclusive rights to manufacturing and commercialization of the first of them, Relifipin, were granted under the partnership agreement to the German pharmaceutical company Bayer. Besides that, NovaMedica has an advanced infrastructure for successful commercialization and promotion of prescription products. See more information at www.novamedica.comPrint
NovaMedica will produce migraine drug Relonova in Moscow
23 March 2023
A resource for anti-tumor drugs testing has been launched in Russia
23 March 2023
Building a Community of Trust in Epilepsy & Rare Syndromes
23 March 2023
Marinus Pharmaceuticals Receives FDA Orphan Drug Designation for Ganaxolone in the Treatment of Lennox-Gastaut Syndrome
22 March 2023